Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aligos Therapeutics Inc
(NQ:
ALGS
)
0.5251
+0.0450 (+9.37%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
508,904
Open
0.4821
Bid (Size)
0.5010 (9)
Ask (Size)
0.5250 (1)
Prev. Close
0.4801
Today's Range
0.4701 - 0.5500
52wk Range
0.3482 - 1.200
Shares Outstanding
42,940,089
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Aligos Therapeutics Announces Reverse Stock Split
August 15, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Strengthens Board with Two New Independent Directors
August 08, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Performance
YTD
-25.98%
-25.98%
1 Month
+4.25%
+4.25%
3 Month
-21.76%
-21.76%
6 Month
-17.93%
-17.93%
1 Year
-41.66%
-41.66%
More News
Read More
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results
August 06, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Recap: Aligos Therapeutics Q4 Earnings
March 12, 2024
Via
Benzinga
Aligos Therapeutics Earnings Preview
March 11, 2024
Via
Benzinga
Aligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024
July 30, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal
July 27, 2024
Via
Talk Markets
Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.
July 22, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB
July 10, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
June 05, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
May 22, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH
May 21, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
ALGS Stock Earnings: Aligos Therapeutics Misses EPS for Q1 2024
May 07, 2024
Via
InvestorPlace
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
May 07, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
April 30, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
April 25, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
April 25, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
April 09, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
April 03, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
March 27, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
March 18, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
March 15, 2024
Via
Benzinga
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
March 12, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Earnings Scheduled For March 12, 2024
March 12, 2024
Via
Benzinga
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
March 05, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.